CPP-BoNT Fusion Proteins for Intramuscular Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current botulinum toxin (BoNT) products face challenges in transdermal delivery and have low therapeutic indices, leading to safety concerns and limited efficacy due to low cellular uptake and high immunogenicity.
Innovation Solution
Development of fusion proteins combining botulinum neurotoxins (BoNTs) with cell-penetrating peptides (CPPs) that are administered intramuscularly, where CPPs enhance cellular uptake and stability, preventing self-cleavage and maintaining enzymatic activity, thereby increasing the therapeutic index and reducing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If botulinum toxin is administered intramuscularly, then therapeutic efficacy is achieved, but therapeutic index is low leading to safety concerns
Solution Approach 1:
The patent combines botulinum toxin with cell-penetrating peptides to create fusion proteins. This merging allows the toxin to be delivered more efficiently into target cells via the CPP mechanism, reducing the overall dose required and thereby improving the therapeutic index while maintaining efficacy.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the botulinum toxin by fusing it with cell-penetrating peptides. This changes the delivery mechanism and cellular uptake characteristics, enabling more precise targeting and reduced off-target effects, thus improving safety and therapeutic index.
2Adaptability or versatility
If botulinum toxin is used for aesthetic and therapeutic applications, then medical indications are expanded, but adverse effects increase
Solution Approach 1:
The patent applies local quality by using cell-penetrating peptides to enhance targeted delivery to specific muscle tissues. This localized delivery mechanism ensures that the botulinum toxin acts primarily at the injection site with minimal systemic distribution, thereby expanding therapeutic applications while reducing adverse effects.
3Productivity
If botulinum toxin is administered, then muscle relaxation is achieved, but cellular uptake is low limiting efficacy
Solution Approach 1:
The patent uses cell-penetrating peptides as intermediary carriers that facilitate the entry of botulinum toxin into target cells. These CPPs act as mediators that exploit cellular uptake mechanisms to transport the toxin across cell membranes, significantly enhancing cellular uptake and thereby improving therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CPP-BoNT fusion proteins exhibit significantly improved cellular uptake, reduced toxicity, and increased therapeutic indices, leading to enhanced muscle shaping effects and prolonged duration of action, with up to 10-fold improvement in therapeutic index compared to commercial products like BOTOX.
Implementation Method 1
These CPP-BONT fusions have exceptional cellular uptake ability
Implementation Method 2
CPPs enhance cellular uptake and stability, preventing self-cleavage and maintaining enzymatic activity
Data Source
AI summary
The present disclosure provides fusion proteins combining botulinum neurotoxins (BoNTs) and cell penetration peptides (CPP) which are suitable for intramuscular administration. These fusion proteins have exceptional cellular uptake ability, potent therapeutic efficacy, and considerably increased therapeutic index when compared to the BoNT protein alone or the commercial product BOTOX® onabotulinumtoxinA. Also provided are BONT fusion proteins that are not cleaved to form two-chain polypeptides but yet retaining strong enzymatic activities. Such single-chain active BONT fusion proteins can be prepared from insect cells.